Ardelyx (NASDAQ:ARDX) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.
This is a summary of current recommendations and price targets for Ardelyx and Akari Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Ardelyx currently has a consensus target price of $11.00, indicating a potential upside of 113.59%. Akari Therapeutics has a consensus target price of $7.00, indicating a potential upside of 291.06%. Given Akari Therapeutics’ higher possible upside, analysts plainly believe Akari Therapeutics is more favorable than Ardelyx.
Valuation and Earnings
This table compares Ardelyx and Akari Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ardelyx||$2.61 million||123.92||-$91.30 million||($1.62)||-3.18|
|Akari Therapeutics||N/A||N/A||-$16.47 million||($0.17)||-10.53|
Akari Therapeutics has lower revenue, but higher earnings than Ardelyx. Akari Therapeutics is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.
This table compares Ardelyx and Akari Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
72.5% of Ardelyx shares are held by institutional investors. Comparatively, 15.7% of Akari Therapeutics shares are held by institutional investors. 15.3% of Ardelyx shares are held by company insiders. Comparatively, 61.8% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk and Volatility
Ardelyx has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of -2.87, meaning that its stock price is 387% less volatile than the S&P 500.
Ardelyx beats Akari Therapeutics on 6 of the 10 factors compared between the two stocks.
Ardelyx Company Profile
Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc is a subsidiary of RPC Pharma Limited.
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.